Radiation Therapy With Concurrent Weekly Carboplatin and Paclitaxol in Advanced Stage Unresectable Squamous Cell Carcinoma of the Head and Neck
James Metz, MD
OncoLink Associate Editor
Last Modified: November 1, 1999
Presenter: Michael L. Haas, MD
Affiliation: University of Maryland
Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer.
From 1993-1998 62 patients received weekly carboplatin/taxol chemotherapy with radiation therapy. Radiation was delivered to a total dose of 70.2 Gy in 1.8 Gy fractions to the primary site. The majority of patients had oropharyngeal cancer.
- The complete response rate was 82% at the primary site and 63% in the neck nodes.
- Overall, 75% had no clinical evidence of residual disease at the completion of therapy.
- With a median follow-up of 30 months, the overall survival at 3 years was 48%.
- The local control rate at 3 years was 63%.
The results of this Phase II study of concurrent chemoradiation are very encouraging for a disease that is notoriously difficult to control. Confirmation of this experience will require Phase III trials.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.